Inovio Pharmaceuticals (NASDAQ:INO) Issues Earnings Results, Beats Estimates By $0.68 EPS

Inovio Pharmaceuticals (NASDAQ:INO) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported $0.31 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.68, FiscalAI reports.

Inovio Pharmaceuticals Stock Down 0.6%

NASDAQ INO traded down $0.01 on Thursday, reaching $1.68. The company had a trading volume of 748,919 shares, compared to its average volume of 1,166,955. The stock has a market capitalization of $112.11 million, a P/E ratio of -0.65 and a beta of 1.70. The company’s fifty day moving average is $1.65 and its 200 day moving average is $2.06. Inovio Pharmaceuticals has a 52-week low of $1.30 and a 52-week high of $2.98.

Institutional Trading of Inovio Pharmaceuticals

Several institutional investors have recently made changes to their positions in INO. Focus Partners Wealth bought a new position in shares of Inovio Pharmaceuticals during the third quarter valued at about $33,000. Raymond James Financial Inc. boosted its holdings in Inovio Pharmaceuticals by 4,396.0% during the third quarter. Raymond James Financial Inc. now owns 16,680 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 16,309 shares during the last quarter. Jacobs Levy Equity Management Inc. bought a new stake in Inovio Pharmaceuticals in the 3rd quarter worth about $41,000. Zacks Investment Management purchased a new stake in Inovio Pharmaceuticals in the 3rd quarter valued at about $46,000. Finally, Caitong International Asset Management Co. Ltd increased its stake in Inovio Pharmaceuticals by 752.9% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 20,572 shares of the biopharmaceutical company’s stock valued at $36,000 after buying an additional 18,160 shares during the last quarter. Institutional investors own 26.79% of the company’s stock.

More Inovio Pharmaceuticals News

Here are the key news stories impacting Inovio Pharmaceuticals this week:

• Positive Sentiment: INO reported Q4 results and beat EPS expectations, reporting $0.31 vs. consensus (?$0.37); management also provided FY commentary. This upside can support sentiment if revenue/cash guidance appears healthy. Quarterly Press Release
• Positive Sentiment: INOVIO announced its Biologics License Application (BLA) for INO-3107 has been accepted under FDA Accelerated Approval (PDUFA target Oct 30, 2026) and highlighted published immunologic/clinical data and new technology progress—news that materially de-risks and derivers potential near- to mid-term value drivers if approval/label is favorable. INOVIO Q4 & BLA Press Release
• Neutral Sentiment: Company science/tech publications and collaborations (Nature Communications, Nature Medicine, Dana-Farber collaboration, DMAb/DPROT preclinical data) signal scientific progress but will take time to translate into revenue; monitor clinical readouts and regulatory milestones. Scientific & Collaboration Details
• Negative Sentiment: Multiple securities-class-action developments: a class action has been filed (Pomerantz; Bronstein reports similar filings/claims alleging investor harm for purchases Oct 10, 2023–Dec 26, 2025), creating potential legal exposure, settlement risk and headline pressure. Pomerantz Filing
• Negative Sentiment: Several law firms (Rosen, Faruqi & Faruqi, Frank R. Cruz, Howard G., Bronstein) are soliciting lead plaintiffs ahead of an April 7, 2026 deadline—this flood of solicitations can amplify selling pressure and prolong volatility even if litigation outcomes are uncertain. Rosen Solicitation

Analyst Ratings Changes

A number of equities analysts have recently weighed in on INO shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inovio Pharmaceuticals in a research report on Monday, December 29th. HC Wainwright restated a “neutral” rating on shares of Inovio Pharmaceuticals in a research note on Tuesday, December 30th. UBS Group restated an “overweight” rating on shares of Inovio Pharmaceuticals in a report on Friday, November 14th. Finally, Piper Sandler reiterated an “overweight” rating and set a $6.00 price objective (up from $5.00) on shares of Inovio Pharmaceuticals in a report on Friday, November 14th. Four equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $6.75.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.